Locoregional therapy in luminal-like and HER2-enriched patients with de novo stage IV breast cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Link
http://link.springer.com/content/pdf/10.1186/2193-1801-2-589.pdf
Reference10 articles.
1. Ali A, Provenzano E, Bartlett JM, et al.: Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. Breast Cancer Res Treat 2000, 63(3):213-223. 10.1023/A:1006468514396
2. Cheng SH, Tsou MH, Liu MC, et al.: Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 2000, 63: 213-223. 10.1023/A:1006468514396
3. Corben AD: Pathology of invasive breast disease. Surg Clin North Am 2013, 93: 363-392. 10.1016/j.suc.2013.01.003
4. Dawood S, Broglio K, Ensor J, et al.: Survival differences among women with de novo stage IV and relapsed breast cancer. Ann Oncol 2010, 21: 2169-2174. 10.1093/annonc/mdq220
5. De Laurentiis M, Arpino G, Massarelli E, et al.: A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005, 11: 4741-4748. 10.1158/1078-0432.CCR-04-2569
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Primary site surgery of de novo stage IV HER2-positive breast cancer in the era of new drug treatments;Frontiers in Oncology;2024-01-09
2. Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database;Breast Cancer;2023-12-03
3. Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology;Frontiers in Oncology;2023-01-30
4. Is there a role for locoregional treatment of the primary tumor in de novo metastatic breast cancer in the era of tailored therapies?;Critical Reviews in Oncology/Hematology;2021-01
5. Establishing a predicted model to evaluate prognosis for initially diagnosed metastatic Her2-positive breast cancer patients and exploring the benefit from local surgery;PLOS ONE;2020-11-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3